TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient Health Questionnaire (PHQ)-9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Log10 HIV-1 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained viral response (HCV RNA < LLOQ TND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of positive patients for extra pulmonary tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain Intensity Score at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity Score at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Osame's motor disability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Lane Position Variability (LPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach anaesthetic depth goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eligible discharge from intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anterior lens capsule vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microvascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of IRS-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of GLUT-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment emergent effects
Endpoint domain: Adverse events/effects
Primary endpoint: Severity and consequences of treatment emergent effects
Endpoint domain: Adverse events/effects
Primary endpoint: prevention of coronary late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in clinical attachment levels (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tanner Pubertal Stage Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMV difference among PNS, PPS and HC groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function-15
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Optical coherence tomography angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excessive daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Catheterization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-instrumentation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-obturation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline fasting blood glucose (FBG) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline C-reactive protein (CRP) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Interleukin-6 (IL-6) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline TNF-alpha at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-State Concentrations in Adipose Tissue Interstitial Fluid (ISF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISF-to-Serum Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Score on the Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade of Primary Graft Dysfunction (PGD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment rate (percentage of patients approached that consent to participate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevention of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cross sectional area of triceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Trough concentration of cefazolin in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma concentrations of cefazolin in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target attainment (100%fT>MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain change at visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of MESIs (Medical Event of Special Interest)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of occurrence of neutralising antibodies against FVII and/or LA-rFVIIa
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lin's Concordance correlation coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of VA Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxygenation status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: speed of the graft warming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Psoriasis Assessment and Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Presence of adenomatous tissue at the base of polypectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resource Utilization and Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Pulmonary Vascular Resistance (Wood Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Who Developed Clinically Significant Adverse Events (CSAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Peg penetration into glenohumeral joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Screw penetration into glenohumeral joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Swallow Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with AST or ALT decline 25% at day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: motivational change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral vasomotor reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean rate of change of non-HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self Reported Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' self-reported Safety Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decline in BIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with fewer than 5 progressively motile sperm per HPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Per-women average number of progressively motile sperm per HPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Hair Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated doses (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Concentration-time Curve from Time 0 to Infinite Time (AUC[0-infinity]) of Apalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve from Time 0 to the Time of the Last Concentration (AUC[0-last]) of Apalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Apalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events PE-related
Endpoint domain: Adverse events/effects
Primary endpoint: Bioequivalence assessment of levofloxacin formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the vector
Endpoint domain: Adverse events/effects
Primary endpoint: AUC 4-OH-diclofenac / AUC diclofenac quantified in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of RAD001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-cuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in relative attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficient ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Loss/recovery of consciousness and responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of supplemental lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain flow hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-year cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hourly 13C-recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elimination Half Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behaviors and attitudes related to violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TCA cycle flux in skeletal muscle and splanchnic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically Significant Increases in Serum Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Investigator-assessed objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Posttraumatic Experience of Mental Contamination (PEMC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Credibility Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Recovery of the T4/T1 Ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Lipid-lowering therapy use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Carotid intima medial tunica change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Responder rate using the Global Aesthetic Improvement Scale (GAIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: level of urinary biomarkers of AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Outcomes of patients with left ventricle non-compaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bypass graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emergence from coma
Endpoint domain: Mortality/survival
Primary endpoint: Cmax of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf for Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological Indicators of stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incision drain output (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying duration per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Quality assessed with Mobility Toolkit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desaturation events during suspension laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and assessment of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Adapted Illness Intrusiveness Ratings (AIIR)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Healthcare Utilization Survey (HCUS)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Blood levels of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin glycosylated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Response Assessment (GRA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evaluation of Efficacy (Otoscopy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LTB4 level in BAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clotting factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rey Auditory Verbal Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State Trait Anxiety Inventory - State (STAIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Perfusion in Regions Of Interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal varices rebleed within 72-hours
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of known SMA positive blood spots not detected by NBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of failed blood spots samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of aplastic anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of High-Risk Plaques (HRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in The WHO-5 Well-Being Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HAI Antibody Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endothelial cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive scale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score on the Questionnaire for Impulsive Disorders in Parkinson's Disease
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score on the Geriatric Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Score on the Barrat Impulsivity Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score on the Minnesota Impulsivity Disorders Interview
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score on the Iowa Gambling Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score on the Montreal Cognitive Impairment Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Understanding of medication instructions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 16 week progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Response rate to RAD induction and transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Sole Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective appetite sensations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Immunomodulatory Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Child Health Questionnaire-Mental Health Subscale (CHQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total area under the curve (tAUC) of GLP-1 hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiovascular structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Preference for paired stimulus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ICU Transfer
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: long-term prognostic impact of residual platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antenatal visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour average pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Impact Scale (SIS-16)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: motion of lung tumours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stress impact on communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extent of neural activation in visual cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first sign of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Who Experienced Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ruminative thinking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in dispositional mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of participants with adverse events following immunization (AEFI)
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal mortality (birth to 28 days of age)
Endpoint domain: Mortality/survival
Primary endpoint: Infant mortality (birth to 365 days)
Endpoint domain: Mortality/survival
Primary endpoint: successful adhesion prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with laboratory-confirmed influenza illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Mean MAX TBR values of the ascending aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the NNC0113-0987 plasma concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evolution of malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status